Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022805 | 0.93 | AKR1C4 (0.66) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL11988493 | 0.87 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL11988496 | 0.87 | AKR1C4 (0.58) | AKR1C4AKR1C3AKR1C2HTT | |
| SCHEMBL10022807 | 0.83 | AKR1C4 (0.66) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL2702818 | 0.83 | AKR1C4 (0.61) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL10053671 | 0.83 | AKR1C4 (0.33) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL11751123 | 0.82 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL21953399 | 0.82 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL29785187 | 0.82 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER4 | |
| SCHEMBL11751129 | 0.82 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247439-B2 | Jasmonate derivatives, pharmaceutical compositions and methods of use thereof | SEPAL PHARMA LTD. (IL) | 2012-08-21 | — | — | US | disclosed |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
| US-20100003346-A1 | COMBINATION METHODS OF TREATING CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-01-07 | — | — | US | disclosed |
| US-20090197927-A1 | JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | SEPAL PHARMA LTD. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197927-A1 | JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALOX5, GGPS1, PPIP5K2 | AKR1C4 1945/4885AKR1C3 1678/4885AKR1C2 1420/4885 |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | MYC, KRT18, DGKK | AKR1C4 390/4885AKR1C3 401/4885AKR1C2 259/4885 |
| US-20100003346-A1 | COMBINATION METHODS OF TREATING CANCER | G6PD, PGD, PDK2 | AKR1C4 460/4885AKR1C3 560/4885AKR1C2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.